

HR 6383

Uterine Fibroid Research and Education Act of 2020

Congress: 116 (2019–2021, Ended)

Chamber: House

Policy Area: Health

Introduced: Mar 24, 2020

Current Status: Referred to the House Committee on Energy and Commerce.

Latest Action: Referred to the House Committee on Energy and Commerce. (Mar 24, 2020)

Official Text: <https://www.congress.gov/bill/116th-congress/house-bill/6383>

Sponsor

Name: Rep. Clarke, Yvette D. [D-NY-9]

Party: Democratic • **State:** NY • **Chamber:** House

Cosponsors (37 total)

Cosponsor	Party / State	Role	Date Joined
Del. Norton, Eleanor Holmes [D-DC-At Large]	D · DC		Mar 24, 2020
Del. Plaskett, Stacey E. [D-VI-At Large]	D · VI		Mar 24, 2020
Rep. Bass, Karen [D-CA-37]	D · CA		Mar 24, 2020
Rep. Bishop, Sanford D., Jr. [D-GA-2]	D · GA		Mar 24, 2020
Rep. Brown, Anthony G. [D-MD-4]	D · MD		Mar 24, 2020
Rep. Butterfield, G. K. [D-NC-1]	D · NC		Mar 24, 2020
Rep. Carson, Andre [D-IN-7]	D · IN		Mar 24, 2020
Rep. Cleaver, Emanuel [D-MO-5]	D · MO		Mar 24, 2020
Rep. Clyburn, James E. [D-SC-6]	D · SC		Mar 24, 2020
Rep. Davis, Danny K. [D-IL-7]	D · IL		Mar 24, 2020
Rep. Fudge, Marcia L. [D-OH-11]	D · OH		Mar 24, 2020
Rep. Hastings, Alcee L. [D-FL-20]	D · FL		Mar 24, 2020
Rep. Jackson Lee, Sheila [D-TX-18]	D · TX		Mar 24, 2020
Rep. Jeffries, Hakeem S. [D-NY-8]	D · NY		Mar 24, 2020
Rep. Johnson, Eddie Bernice [D-TX-30]	D · TX		Mar 24, 2020
Rep. Johnson, Henry C. "Hank," Jr. [D-GA-4]	D · GA		Mar 24, 2020
Rep. Kelly, Robin L. [D-IL-2]	D · IL		Mar 24, 2020
Rep. Lawrence, Brenda L. [D-MI-14]	D · MI		Mar 24, 2020
Rep. Lee, Barbara [D-CA-13]	D · CA		Mar 24, 2020
Rep. Meeks, Gregory W. [D-NY-5]	D · NY		Mar 24, 2020
Rep. Pressley, Ayanna [D-MA-7]	D · MA		Mar 24, 2020
Rep. Richmond, Cedric L. [D-LA-2]	D · LA		Mar 24, 2020
Rep. Rush, Bobby L. [D-IL-1]	D · IL		Mar 24, 2020
Rep. Scott, David [D-GA-13]	D · GA		Mar 24, 2020
Rep. Thompson, Bennie G. [D-MS-2]	D · MS		Mar 24, 2020
Rep. Watson Coleman, Bonnie [D-NJ-12]	D · NJ		Mar 24, 2020
Del. San Nicolas, Michael F. Q. [D-GU-At Large]	D · GU		Jun 15, 2020
Rep. Barragan, Nanette Diaz [D-CA-44]	D · CA		Jun 15, 2020
Rep. Cárdenas, Tony [D-CA-29]	D · CA		Jun 15, 2020
Rep. Grijalva, Raúl M. [D-AZ-3]	D · AZ		Jun 15, 2020
Rep. Soto, Darren [D-FL-9]	D · FL		Jun 15, 2020
Rep. Velazquez, Nydia M. [D-NY-7]	D · NY		Jun 15, 2020
Rep. Gallego, Ruben [D-AZ-7]	D · AZ		Jul 9, 2020
Rep. Gonzalez, Vicente [D-TX-15]	D · TX		Jul 9, 2020
Rep. Titus, Dina [D-NV-1]	D · NV		Jul 9, 2020
Rep. McBath, Lucy [D-GA-6]	D · GA		Aug 28, 2020
Rep. Sewell, Terri A. [D-AL-7]	D · AL		Nov 17, 2020

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred To	Mar 24, 2020

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
116 S 4397	Identical bill	Aug 3, 2020: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Summary (as of Mar 24, 2020)

Uterine Fibroid Research and Education Act of 2020

This bill directs specified components of the Department of Health and Human Services to take certain actions to address uterine fibroids (i.e., muscular tumors that grow in the wall of the uterus and may cause pain, heavy menstrual bleeding, and reproductive issues).

Specifically, the National Institutes of Health (NIH), working through the Office of Research on Women's Health, must undertake research activities on uterine fibroids. In carrying out this research, the office must coordinate with specified components of the NIH and other federal agencies.

In addition, the Centers for Medicare & Medicaid Services must (1) collect data from Medicaid and the Children's Health Insurance Program about treatment and services related to uterine fibroids, and (2) develop a report in coordination with federal partners on federal and state expenditures for these treatments and services.

Additionally, the Centers for Disease Control and Prevention (CDC), the Health Resources Service Administration (HRSA), and the Agency for Healthcare Research and Quality (AHRQ) must disseminate information about uterine fibroids, including the elevated risk for minority women and information regarding available treatments. Specifically, the CDC shall disseminate the information to the public, while HRSA and AHRQ shall disseminate it to health care providers.

Actions Timeline

- **Mar 24, 2020:** Introduced in House
- **Mar 24, 2020:** Referred to the House Committee on Energy and Commerce.